How does tesofensine work?

Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide. This site's profile says it blocks reuptake of noradrenaline, dopamine, and serotonin, increasing satiety signaling and reducing food intake. Half-life is about 8 days. Molecular weight is 381.9 daltons. It is investigational and not FDA approved. A Phase 2 trial in 203 people reported 4.5%, 9.2%, and 10.6% weight loss at 24 weeks versus 2.0% on placebo, with resting heart rate up 7.4 bpm at 0.5 mg. The Lancet published an Expression of Concern about that trial in April 2013; the paper has not been retracted and remains the main human efficacy result on this page, labelled. A sub-study found the weight change was driven mainly by reduced appetite and energy intake, not a measured fat-oxidation result. Appearing on a peptide storefront does not make it a peptide. This FAQ does not invent a dose. Full record at /compounds/tesofensine.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.